However, recent studies have found that treatment of KRASG12C allele-specific inhibitors or SHP2 inhibitors, or MEK inhibitors could activate anti-tumor immune cells and thereby relieve immunosuppressive status, which improves the response of KRAS-mutant CRC to immune checkpoint inhibitors in preclinical models [66, 87, 88, 130]. The gene discussed is PTPN11; the disease is colorectal carcinoma.